Unprotected individuals with known or presumed exposure to the hepatitis B virus (e.g., neonates born of infected mothers, others experiencing percutaneous or permucosal exposure) should be given hepatitis B immune globulin (HBIG) in addition to ENGERIX-B in accordance with ACIP recommendations1 and with the package insert for HBIG. ENGERIX-B can be given on either dosing schedule (see above).
Store refrigerated between 2° and 8°C (36° and 46°F). Do not freeze ; discard if product has been frozen. Do not dilute to administer.
ENGERIX-B is supplied as a slightly turbid white suspension in vials and prefilled TIP-LOK® syringes.
They are supplied by Dispensing Solutions Inc. as follows:
Adult Dose (Preservative Free Formulation)
|68258-3042-1||20 ug/1 mL||1 ml Single Dose Vial||WHITE||58160-821-11|
This product was Manufactured By:
Rixensart, Belgium, US License No. 1617
Distributed by GlaxoSmithKline
Research Triangle Park, NC 27709
And Repackaged By:
Dispensing Solutions Inc.
3000 West Warner Ave
Santa Ana, CA 92704
1. Centers for Disease Control and Prevention. Hepatitis B. In: Atkinson W, Wolfe C, Humiston S, Nelson R, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 6th ed. Atlanta, GA: Public Health Foundation; 2000:207-229. 2. Beasley RP, Hwang L-Y, Stevens CE, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983;3(2):135-141. 3. Centers for Disease Control and Prevention. New vaccine information materials for hepatitis B, haemophilus influenzae type B (Hib), and varicella (chickenpox) vaccines, and revised vaccine information materials for measles, mumps, rubella (MMR) vaccines. Federal Register. February 23, 1999;64(35):9044-9045. 4. Chang M-H, Chen C-J, Lai M-S, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 1997;336(26):1855-1859. 5. Lee M-S, Kim D-H, Kim H, et al. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea. Int J Epidemiol. 1998;27(2):316-319. 6. Centers for Disease Control and Prevention. Effectiveness of a seventh grade school entry vaccination requirement ― statewide and Orange County, Florida, 1997-1998. MMWR. 1998;47(34):711-715. 7. American Academy of Pediatrics. Universal hepatitis B immunization. Pediatrics. 1992;89(4):795-800. 8. Centers for Disease Control and Prevention. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. MMWR. 1996;45(RR-13):1-16. 9. American Academy of Pediatrics. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. Pediatrics. 1997;99(3):479-488. 10. André FE and Safary A. Clinical experience with a yeast-derived hepatitis B vaccine. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York, NY: Alan R Liss, Inc.; 1988:1025-1030. 11. Poovorawan Y, Sanpavat S, Pongpunlert W, et al. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA. 1989;261(22):3278-3281. 12. Stevens CE, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in patients receiving hemodialysis. N Engl J Med. 1984;311(8):496-501. 13. Hauser P, Voet P, Simoen E, et al. Immunological properties of recombinant HBsAg produced in yeast. Postgrad Med J. 1987;63(suppl 2):83-91. 14. Bush LM, Moonsammy GI, Boscia JA. Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. Vaccine. 1991;9(11):807-809. 15. Goilav C, Prinsen H, Safary A, et al. Immunization of homosexual men with a recombinant DNA vaccine against hepatitis B: immunogenicity and protection. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York, NY: Alan R Liss, Inc.; 1988:1057-1058. 16. Centers for Disease Control and Prevention. 1998 Guidelines for treatment of sexually transmitted diseases. MMWR. 1998;47(RR-1):102. 17. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1994;43(RR-1):1-38. 18. Centers for Disease Control. National Childhood Vaccine Injury Act: requirements for permanent vaccination records and for reporting of selected events after vaccination. MMWR. 1988;37(13):197-200. 19. Public Health Service. National Vaccine Injury Compensation Program: revision of the vaccine injury table. Federal Register. February 8, 1995;60(26):7694.
* Yeast-derived, Hepatitis B Vaccine, MSD.
ENGERIX-B and TIP-LOK are registered trademarks of GlaxoSmithKline.
RECOMBIVAX HB is a registered trademark of Merck & Co.
| ENGERIX-B |
hepatitis b vaccine (recombinant) injection, suspension
|Labeler — Dispensing Solutions Inc. (066070785)|
|Dispensing Solutions Inc.||066070785||repack, relabel|
Revised: 03/2010 Dispensing Solutions Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.